How Are Payers Prepared To Value Clinical Evidence In Cardiovascular Medicine?
Sunday December 6th: 6:00 – 8:00 pm
Always a difficult subject, the question, “How can we pay for this (medication, device, procedure)?” When we have our trialists’ hats on, we sometimes forget the day-to-day practicalities of accessing new and exciting treatments for our patients.
This session will be co-chaired by two clinicians with extensive experience on the payer side of the aisle, Prof. Martin Cowie and Dr. Joseph Hutter. Prof. Cowie is a Cardiologist at the Royal Brompton and Harefield NHS Foundation Trust, and he has worked extensively with the National Institute for Health and Care Excellence (NICE) in the areas of atrial fibrillation and heart failure. Dr. Hutter is Lead Medical Officer for the Centers for Medicare and Medicaid Services (CMS), at the Center for Clinical Standards and Quality in Baltimore, Maryland, USA.
While the evidence may demonstrate that a new treatment is statistically significantly superior to another treatment; what does that result mean, clinical and to society in general? Is the new intervention marginally more effective, is it life-saving? Measuring the “value” of an intervention remains ill defined, since no single viewpoint can adequately capture the perspective of all relevant parties. In order to provide sustainable access to high-value care for all patients, there is a need to balance “long-term value for money” and “short-term affordability”. During this session we will look at value-based medicine, including post-approval and real world cost-effectiveness studies.
Speakers include a cardiologist, Javed Butler (Jackson, USA), and a payer, Jason Bennett (CMS, USA), with viewpoints from multiple other stakeholders, including: health economists (Andrew Briggs, LSHTM, GBR), industry (Maria Kubin, Bayer, GER), payers (Adrian Jonas, NICE, London, GBR), clinicians (Amanda Adler, Cambridge, GBR), and patients (Bray Patrick-Lake, Durham, USA).
After the session, join the panel with additional representatives of clinical, payer, and industry viewpoints, as well as regulatory agencies, when they turn the topic around and discuss the question: “How Are Trialists Prepared To Listen To Payer’s Needs?”